Evidence that ALK fusions are strong oncogenic drivers across tumor types suggests that ALK inhibitors may have tumor-agnostic activity; however, due to the rarity of ALK fusions, investigating the efficacy of ALK inhibitors in indications beyond NSCLC is challenging.3 Thus, the characteristics and natural history of patients with tumors harboring ALK fusions other than NSCLC have not been widely studied. This evidence concerns the gene ALK and non-small cell lung carcinoma.